BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 17222753)

  • 21. Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling.
    Lee JW; Kang HJ; Lee SH; Yu KS; Kim NH; Yuk YJ; Jang MK; Han EJ; Kim H; Song SH; Park KD; Shin HY; Jang IJ; Ahn HS
    Biol Blood Marrow Transplant; 2012 Jun; 18(6):944-50. PubMed ID: 22155501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetics of dimethylacetamide in children during standard and once-daily IV busulfan administration.
    Trame MN; Bartelink IH; Boos J; Boelens JJ; Hempel G
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1149-55. PubMed ID: 24036908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation.
    Sato M; Kako S; Matsumoto K; Oshima K; Akahoshi Y; Nakano H; Ugai T; Yamasaki R; Wada H; Ishihara Y; Sakamoto K; Kawamura K; Ashizawa M; Terasako-Saito K; Kimura S; Nakasone H; Kikuchi M; Tanihara A; Yamazaki R; Tanaka Y; Kanda J; Nishida J; Morita K; Kanda Y
    Int J Hematol; 2015 May; 101(5):497-504. PubMed ID: 25672602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation.
    Jacobson P; Park JJ; DeFor TE; Thrall M; Abel S; Krivit W; Peters C
    Bone Marrow Transplant; 2001 Apr; 27(8):855-61. PubMed ID: 11477444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integration of modelling and simulation into the development of intravenous busulfan in paediatrics: an industrial experience.
    Nguyen L
    Fundam Clin Pharmacol; 2008 Dec; 22(6):599-604. PubMed ID: 19049661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
    Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Quigley J; Chen YH; Mahmud N; Hurter E; Beri R; Rondelli D
    Bone Marrow Transplant; 2008 Jun; 41(11):935-40. PubMed ID: 18264144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial.
    Veal GJ; Nguyen L; Paci A; Riggi M; Amiel M; Valteau-Couanet D; Brock P; Ladenstein R; Vassal G
    Eur J Cancer; 2012 Nov; 48(16):3063-72. PubMed ID: 22742881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan.
    Bonin M; Pursche S; Bergeman T; Leopold T; Illmer T; Ehninger G; Schleyer E; Bornhauser M
    Bone Marrow Transplant; 2007 Feb; 39(4):201-6. PubMed ID: 17211431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.
    Mannis GN; Andreadis C; Logan AC; Damon LE; Benet LZ; Ai WZ; Gaensler KM; Kaplan LD; Koplowicz YB; Linker CA; Olin RL; Sayre PH; Smith CC; Sudhindra A; Venstrom JM; Wolf JL; Martin TG
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):377-83. PubMed ID: 25776193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.
    Tran H; Petropoulos D; Worth L; Mullen CA; Madden T; Andersson B; Choroszy M; Nguyen J; Webb SK; Chan KW
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):805-12. PubMed ID: 15505611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant.
    Tse WT; Duerst R; Schneiderman J; Chaudhury S; Jacobsohn D; Kletzel M
    Bone Marrow Transplant; 2009 Aug; 44(3):145-56. PubMed ID: 19182832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation.
    Perkins JB; Kim J; Anasetti C; Fernandez HF; Perez LE; Ayala E; Kharfan-Dabaja MA; Tomblyn MR; Sullivan DM; Pidala JA; Field TL
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1099-107. PubMed ID: 22198540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once-daily intravenous busulfan for 47 pediatric patients undergoing autologous hematopoietic stem cell transplantation: a single center study.
    González-Vicent M; Molina B; Pérez A; Díaz MA
    J Pediatr Hematol Oncol; 2012 Apr; 34(3):180-3. PubMed ID: 22430583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.
    Nguyen L; Fuller D; Lennon S; Leger F; Puozzo C
    Bone Marrow Transplant; 2004 May; 33(10):979-87. PubMed ID: 15064687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pretransplant conditioning in adults and children: dose assurance with intravenous busulfan.
    Fisher VL; Barnes YJ; Nuss SL
    Oncol Nurs Forum; 2006 Nov; 33(2):E36-43. PubMed ID: 16518436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation.
    de Castro FA; Lanchote VL; Voltarelli JC; Colturato VA; Simões BP
    J Clin Pharmacol; 2013 Nov; 53(11):1205-11. PubMed ID: 23955479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and tolerability of intravenous busulfan in hematopoietic stem cell transplantation.
    Cho YH; Lim HA; Lee MH; Kim I; Lee JS; Park Sy; Kim BK; Yoon SS
    Clin Transplant; 2007; 21(3):417-22. PubMed ID: 17488395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies.
    Zia-Amirhosseini P; Hurd DD; Salfi M; Cheah TC; Aycock J; Cesano A
    Pharmacotherapy; 2007 Oct; 27(10):1353-60. PubMed ID: 17896890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetics of oral busulfan in children.
    Schiltmeyer B; Klingebiel T; Schwab M; Mürdter TE; Ritter CA; Jenke A; Ehninger G; Gruhn B; Würthwein G; Boos J; Hempel G
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):209-16. PubMed ID: 12811512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes.
    Perkins J; Field T; Kim J; Kharfan-Dabaja MA; Ayala E; Perez L; Fernandez H; Fancher K; Tate C; Shaw LM; Milone MC; Gardiner JA; Miller S; Anasetti C
    Bone Marrow Transplant; 2011 Nov; 46(11):1418-25. PubMed ID: 21132026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.